Isolation, molecular identification, and antifungal susceptibility profiles of vaginal isolates of Candida species

Background and Objectives: Vulvovaginal candidiasis is a common fungal infection among women during reproductive ages. Although, Candida albicans is accounted as the main etiologic agent of vaginitis, non-albicans species have arisen during last years. Resistant to antifungal drugs especially, fluconazole has been more reported by researchers from around the World. The aims of this study were to determine the prevalence of vulvovaginal candidiasis among suspected patients with vaginitis, the frequency of Candida species, and the susceptibility profiles of isolates to caspofungin, fluconazole and clotrimazole. Materials and Methods: One hundred and twenty suspected women with vaginitis were examined by specialist physician and sampled using moisture swabs. Swabs were inoculated on CHROMagar Candida plates, incubated at 35°C and detected all isolated Candida species using morphological, microcopy and molecular methods. The antifungal susceptibility tests with caspofungin, fluconazole and clotrimazole were applied using microdilution and Resazurin dye methods against all isolated yeasts. Results: The cultures were positive for 34(28.3%) samples and three Candida species including; C. albicans (88.2%), C. glabrata (8.8%) and C. kefyr (2.9%). Our study shows that only one isolate of C. albicans was resistant to caspofungin at the concentration of 2 μg/ml after 24h incubation that increased to 2 isolates after 48h incubation. All isolates were sensitive to fluconazole at the MIC ranges of 1-0.25 μg/ml, while 88.2% of them were inhibited at 0.25 μg/mL of clotrimazole. Candida albicans remains the most common agent of fungal vaginitis. Conclusion: Although all of Candida isolates were susceptible to fluconazole in vitro, it should be used with caution for empirical therapy due to more resistant rates in clinic. In addition, due to valuable sensitivity of all tested strains to caspofungin, it potentially can be presented as the first line therapy for Candida vaginitis.

[1]  B. Foxman,et al.  Recurrent vulvovaginal candidiasis. , 2017, Annals of epidemiology.

[2]  M. Consolaro,et al.  Highlights Regarding Host Predisposing Factors to Recurrent Vulvovaginal Candidiasis: Chronic Stress and Reduced Antioxidant Capacity , 2016, PloS one.

[3]  H. Bai,et al.  Species Distribution and In Vitro Antifungal Susceptibility of Vulvovaginal Candida Isolates in China , 2016, Chinese Medical Journal.

[4]  M. Díaz,et al.  [Identification and in vitro antifungal susceptibility of vaginal Candida spp. isolates to fluconazole, clotrimazole and nystatin]. , 2016, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[5]  Yiheng Liang,et al.  Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis , 2016, Health and Quality of Life Outcomes.

[6]  P. Dunlop,et al.  Resazurin-based 96-well plate microdilution method for the determination of minimum inhibitory concentration of biosurfactants , 2016, Biotechnology Letters.

[7]  V. Vicente,et al.  Susceptibility and molecular characterization of Candida species from patients with vulvovaginitis , 2016, Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology].

[8]  A. Bitew,et al.  Spectrum and the In Vitro Antifungal Susceptibility Pattern of Yeast Isolates in Ethiopian HIV Patients with Oropharyngeal Candidiasis , 2016, International journal of microbiology.

[9]  Z. Nasrollahi,et al.  Fluconazole Resistance Candida albicans in Females With Recurrent Vaginitis and Pir1 Overexpression , 2015, Jundishapur journal of microbiology.

[10]  J. Mohamadi,et al.  Antifungal drug resistance pattern of Candida. spp isolated from vaginitis in Ilam-Iran during 2013-2014 , 2015, Bioinformation.

[11]  Yiming Fan,et al.  Molecular identification and antifungal susceptibility of 186 Candida isolates from vulvovaginal candidiasis in southern China. , 2015, Journal of medical microbiology.

[12]  Z. Taheri,et al.  Isolation of Different Species of Candida in Patients With Vulvovaginal Candidiasis From Sari, Iran , 2015, Jundishapur journal of microbiology.

[13]  Z. Khan,et al.  Species spectrum and antifungal susceptibility profile of vaginal isolates of Candida in Kuwait. , 2015, Journal de mycologie medicale.

[14]  A. Zarei Mahmoudabadi,et al.  The Susceptibility Patterns of Candida Species Isolated From Urine Samples to Posaconazole and Caspofungin , 2015, Jundishapur journal of microbiology.

[15]  Z. Seifi,et al.  Extracellular Enzymes and Susceptibility to Fluconazole in Candida Strains Isolated From Patients With Vaginitis and Healthy Individuals , 2015, Jundishapur journal of microbiology.

[16]  W. Mendling.  Guideline: Vulvovaginal Candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis) , 2015, Mycoses.

[17]  S. Fan,et al.  Prevalence of Candida nivariensis and Candida bracarensis in Vulvovaginal Candidiasis , 2014, Mycopathologia.

[18]  G. Garcia-Effron,et al.  Epidemiology and Antifungal Susceptibilities of Yeasts Causing Vulvovaginitis in a Teaching Hospital , 2014, Mycopathologia.

[19]  H. Zhang,et al.  Species distribution and susceptibility of Candida isolates from patient with vulvovaginal candidiasis in Southern China from 2003 to 2012. , 2014, Journal de mycologie medicale.

[20]  J. Nosanchuk,et al.  The impact of antifungals on toll-like receptors , 2014, Front. Microbiol..

[21]  M. Asadi,et al.  Vaginal Candidiasis Complications on Pregnant Women , 2014, Jundishapur journal of microbiology.

[22]  M. Ilkit,et al.  Clinical Characteristics of Turkish Women with Candida krusei Vaginitis and Antifungal Susceptibility of the C. krusei Isolates , 2013, Infectious diseases in obstetrics and gynecology.

[23]  K. Makimura,et al.  Molecular identification and distribution profile of Candida species isolated from Iranian patients. , 2013, Medical mycology.

[24]  E. Moghimipour,et al.  Lamisil versus clotrimazole in the treatment of vulvovaginal candidiasis , 2013, Iranian journal of microbiology.

[25]  J. Domínguez-Roldán,et al.  Efficacy and safety of caspofungin in critically ill patients. ProCAS Study. , 2012, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[26]  H. Hanifian,et al.  Rapid identification of drug resistant Candida species causing recurrent vulvovaginal candidiasis. , 2012, Medical mycology journal.

[27]  W. Mendling,et al.  Guideline vulvovaginal candidosis (2010) of the german society for gynecology and obstetrics, the working group for infections and infectimmunology in gynecology and obstetrics, the german society of dermatology, the board of german dermatologists and the german speaking mycological society , 2012, Mycoses.

[28]  S. Ray,et al.  Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection. , 2011, The Cochrane database of systematic reviews.

[29]  H. Shokri,et al.  Antifungal efficacy of propolis against fluconazole‐resistant Candida glabrata isolates obtained from women with recurrent vulvovaginal candidiasis , 2011, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[30]  M. Mahmoudi Rad,et al.  The epidemiology of Candida species associated with vulvovaginal candidiasis in an Iranian patient population. , 2011, European journal of obstetrics, gynecology, and reproductive biology.

[31]  W. Mendling,et al.  Management of Recurrent Vulvo-Vaginal Candidosis as a Chronic Illness , 2010, Gynecologic and Obstetric Investigation.

[32]  R. Heshmat,et al.  Vulvovaginal candidiasis and its related factors in diabetic women. , 2007, Taiwanese journal of obstetrics & gynecology.

[33]  A. Kapil,et al.  Prevalence & susceptibility to fluconazole of Candida species causing vulvovaginitis. , 2007, The Indian journal of medical research.

[34]  Sergey V. Balashov,et al.  Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1 , 2006, Antimicrobial Agents and Chemotherapy.

[35]  M. Sorbello,et al.  Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients. , 2006, Transplantation proceedings.

[36]  D. Denning,et al.  Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  K. Marr,et al.  Mechanism of Increased Fluconazole Resistance in Candida glabrata during Prophylaxis , 2004, Antimicrobial Agents and Chemotherapy.

[38]  J. Sobel,et al.  Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  J. Smietana,et al.  A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. , 2002, The American journal of medicine.

[40]  M. Gilani,et al.  RECOVERY AND RECURRENCE OF VAGINAL CANDIDIASIS AFTER ORAL AND INTRAVAGINAL TREATMENT , 2000 .

[41]  J. Garnacho-Montero,et al.  Efficacy and safety of caspofungin in critically ill patients , 2012 .

[42]  A. Mahmoudabadi,et al.  CLINICAL STUDY OF CANDIDA VAGINITIS IN AHVAZ, IRAN AND SUSCEPTIBILITY OF AGENTS TO TOPICAL ANTIFUNGAL , 2010 .

[43]  T. White.  Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics , 1990 .